# EDGAR Filing Document

**Accession Number:** 0000901832
**File Stem:** 0001104659-26-005772
**Filing Date:** 2026-1
**Character Count:** 4691
**Document Hash:** d10ec041a2053d7ef999768fe72b7336
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-005772.hdr.sgml**: 20260122

**ACCESSION NUMBER**: 0001104659-26-005772

**CONFORMED SUBMISSION TYPE**: 8-A12B

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260122

**DATE AS OF CHANGE**: 20260122

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASTRAZENECA PLC
- **CENTRAL INDEX KEY:** 0000901832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11960
- **FILM NUMBER:** 26551524

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA
- **BUSINESS PHONE:** 011 44 20 7304 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZENECA GROUP PLC
- **DATE OF NAME CHANGE:** 19930422

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**<br> **WASHINGTON, D.C. 20549**

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES<br> PURSUANT TO SECTION 12(b) OR (g) OF THE<br> SECURITIES EXCHANGE ACT OF 1934**

**AstraZeneca PLC**<br> (Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **England and Wales**<br> (State or other jurisdiction of incorporation or<br> organization) | **Not Applicable**<br> (I.R.S. Employer<br> Identification No.) |
| **1 Francis Crick Avenue<br> Cambridge Biomedical Campus<br> Cambridge, United Kingdom**<br> (Address of principal executive offices) | **CB2 0AA**<br> (Zip Code) |

---

**Securities to be registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **Title of each class<br> to be so registered** | **Name of each exchange on which<br> each class is to be registered** |
| Ordinary Shares of 25¢ each | The New York Stock Exchange |

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ⌧

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ◻

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ◻

Securities Act registration statement or Regulation A offering statement file number to which this form relates: **Not applicable.**

Securities to be registered pursuant to Section 12(g) of the Act: **None.**

**EXPLANATORY NOTE**

AstraZeneca PLC ("AstraZeneca" or, the "Registrant") is filing this Form 8-A with the Securities and Exchange Commission (the "SEC") in connection with the listing of AstraZeneca's ordinary shares of 25¢ each (the "Ordinary Shares") on the New York Stock Exchange.

**INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**Item 1. Description of Registrant's Securities to Be Registered.**

AstraZeneca hereby incorporates by reference the description of AstraZeneca's Ordinary Shares under the caption "Ordinary Shares" included in Exhibit 2.1 to AstraZeneca's Annual Report on Form 20-F for the year ended December 31, 2024 (File No. 001-11960), filed with the SEC on February 18, 2025 (the "2024 Annual Report").

**Item 2. Exhibits.**

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed as part of this Registration Statement on Form 8-A because no other securities of the Registrant are registered on the New York Stock Exchange and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Dated: January 22, 2026 | **AstraZeneca PLC** | **AstraZeneca PLC** | **AstraZeneca PLC** |
|  | (Registrant) | (Registrant) | (Registrant) |
|  | By: | /s/ Matthew Bowden | /s/ Matthew Bowden |
|  |  | Name: | Matthew Bowden |
|  |  | Title: | Company Secretary |

---